MedPacto (Korea) Performance
| 235980 Stock | KRW 4,650 50.00 1.06% |
The company secures a Beta (Market Risk) of 0.69, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, MedPacto's returns are expected to increase less than the market. However, during the bear market, the loss of holding MedPacto is expected to be smaller as well. At this point, MedPacto has a negative expected return of -0.46%. Please make sure to verify MedPacto's mean deviation, standard deviation, total risk alpha, as well as the relationship between the coefficient of variation and jensen alpha , to decide if MedPacto performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days MedPacto has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Total Cashflows From Investing Activities | -77.8 B |
MedPacto |
MedPacto Relative Risk vs. Return Landscape
If you would invest 639,000 in MedPacto on September 20, 2024 and sell it today you would lose (174,000) from holding MedPacto or give up 27.23% of portfolio value over 90 days. MedPacto is generating negative expected returns and assumes 3.6024% volatility on return distribution over the 90 days horizon. Simply put, 32% of stocks are less volatile than MedPacto, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
MedPacto Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for MedPacto's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MedPacto, and traders can use it to determine the average amount a MedPacto's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1268
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 235980 |
Estimated Market Risk
| 3.6 actual daily | 32 68% of assets are more volatile |
Expected Return
| -0.46 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average MedPacto is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MedPacto by adding MedPacto to a well-diversified portfolio.
MedPacto Fundamentals Growth
MedPacto Stock prices reflect investors' perceptions of the future prospects and financial health of MedPacto, and MedPacto fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MedPacto Stock performance.
| Return On Equity | -58.54 | |||
| Return On Asset | -0.25 | |||
| Current Valuation | 1.18 T | |||
| EBITDA | (26.36 B) | |||
| Cash And Equivalents | 1.29 B | |||
| Total Debt | 75.41 B | |||
| Debt To Equity | 0.01 % | |||
| Cash Flow From Operations | (25.15 B) | |||
| Total Asset | 133.35 B | |||
About MedPacto Performance
By analyzing MedPacto's fundamental ratios, stakeholders can gain valuable insights into MedPacto's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if MedPacto has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MedPacto has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers MS-1601A that targets TRG1 for cancers and autoimmune diseases and vactosertib for solid tumors. MedPacto is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about MedPacto performance evaluation
Checking the ongoing alerts about MedPacto for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MedPacto help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MedPacto generated a negative expected return over the last 90 days | |
| MedPacto has high historical volatility and very poor performance | |
| Net Loss for the year was (17.04 B) with loss before overhead, payroll, taxes, and interest of (1.66 M). | |
| MedPacto has accumulated about 1.29 B in cash with (25.15 B) of positive cash flow from operations. | |
| Roughly 34.0% of the company shares are owned by insiders or employees |
- Analyzing MedPacto's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MedPacto's stock is overvalued or undervalued compared to its peers.
- Examining MedPacto's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MedPacto's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MedPacto's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MedPacto's stock. These opinions can provide insight into MedPacto's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for MedPacto Stock analysis
When running MedPacto's price analysis, check to measure MedPacto's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MedPacto is operating at the current time. Most of MedPacto's value examination focuses on studying past and present price action to predict the probability of MedPacto's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MedPacto's price. Additionally, you may evaluate how the addition of MedPacto to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |